Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age3-18
SponsorNeolys
About this trial
Analysis of the individual radiosensitivity in pediatric oncology
Eligibility criteria
Qualifiers
Minor patient treated for a brain tumor, Ewing tumor, malignant mesenchymal tumor, neuroblastoma, nephroblastoma, Hodgkin's lymphoma treated with radiotherapy (+/- chemotherapy) for curative purposes.
Children or adolescents > 3 years old and < 18 years old
Patient with an indication for radiotherapy as part of the primary tumor local control strategy
Theoretical indication for radiotherapy in standard fractionation (1.8 Gy to 2.2 Gy / fraction: 5 fr/week) whatever the technique and the particle used
Disqualifiers
Patients with contraindications to blood sampling
Patients with contraindications to radiotherapy
Palliative radiotherapy
Patient with previous RT treatment in the same area (re-irradiation)
Trial design
Treatments tested in this trial
- Blood sample
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Neolys
Lead sponsor
Centre Francois Baclesse
Collaborator
Centre Hospitalier Universitaire de Caen
Collaborator
Institut de cancérologie Strasbourg Europe
Collaborator
Centre Oscar Lambret, Lille, France
Collaborator
Source ClinicalTrials.gov